Buckman Co. v. Plaintiffs' Legal Committee

Background

Respondent represents people who say they were injured by orthopedic bone screws implanted in their spines. A consulting company helped the screws’ manufacturer apply to the Food and Drug Administration (FDA) for market approval. The patients allege the consultant made false statements in the FDA filings that caused the devices to be cleared and later caused their injuries. Many related lawsuits were consolidated in a multidistrict litigation docket.

Reasoning

The Court addressed whether state-law claims that accuse a company of defrauding the FDA conflict with federal law. The Justices explained that the Medical Device Amendments and the FDA’s regulatory scheme give the federal government the tools to police and punish fraud in device applications. Allowing state tort suits would upset the balance the FDA is charged to strike, could burden applicants and delay the agency’s §510(k) approval process, and would interfere with accepted practices such as off‑label medical use. For these reasons, the Court held such state fraud-on-the-FDA claims are impliedly pre-empted.

Real world impact

The ruling prevents patients from using state fraud claims to attack FDA approval decisions and shifts primary enforcement to federal authorities. It may reduce the number of state damage lawsuits tied to FDA filings and could affect how companies prepare applications. The decision does not rule on express pre-emption issues or on cases where the FDA has already determined fraud and removed a device from the market.

Dissents or concurrances

Justice Stevens, joined by Justice Thomas, agreed the case should be dismissed but emphasized that the plaintiffs also could not prove causation because the FDA had not removed the devices; he warned the Court’s broad pre-emption view might be too sweeping.